Obesity, inflammation, and the gut microbiota

The Lancet Diabetes and Endocrinology

Volumn 3, Issue 3, 2015, Pages 207-215

  Cox, Amanda J ^a   West, Nicholas P ^a   Cripps, Allan W ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CYTOKINE; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE BINDING PROTEIN; SHORT CHAIN FATTY ACID; TIGHT JUNCTION PROTEIN; TOLL LIKE RECEPTOR 4; BIOLOGICAL MARKER;

CYTOKINE PRODUCTION; DIET; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENDOTOXEMIA; HUMAN; INFLAMMATION; INTESTINE EPITHELIUM CELL; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; TIGHT JUNCTION; BIOLOGICAL MODEL; COMPLICATION; GASTROINTESTINAL TRACT; METABOLISM; MICROBIOLOGY; MICROFLORA; PERMEABILITY; PREVALENCE;

BIOLOGICAL MARKERS; GASTROINTESTINAL TRACT; HUMANS; INFLAMMATION; MICROBIOTA; MODELS, BIOLOGICAL; OBESITY; PERMEABILITY; PREVALENCE;

EID: 84924066289     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(14)70134-2     Document Type: Review

References (106)

1. About obesity World Obesity Federation, (accessed Jan 16, 2014). http://www.iaso.org/resources/aboutobesity/.
2. Global Health Risks-mortality and burden of disease attributable to selected major risks WHO, (accessed Jan 16, 2014). http://www.who.int.healthinfo/global_burden_disease/GlobalHealthRisks_report_full.pdf.
3. Health. United States Centers for Disease Control and Prevention, (accessed Jan 16, 2014). http://www.cdc.gov/nchs/data/hus/hus12.pdf.
4. Statistics on obesity, physical activity and diet: England Health and Social Care Information Centre, (accessed Jan 16, 2014). http://www.hscic.gov.uk/catalogue/PUB10364/obes-phys-acti-diet-eng-2013-rep.pdf.
5. Australian Health Survey, 2011-2012 Australian Bureau of Statistics, (accessed Jan 16, 2014). http://www.ausstats.abs.gov.au/Ausstats/subscriber.nsf/0/1680ECA402368CCFCA257AC90015AA4E/$File/4364.0.55.001.pdf.
6. Cawley J, Meyerhoefer C The medical care costs of obesity: an instrumental variables approach. J Health Econ 2012, 31:219-230.
7. Choi J, Joseph L, Pilote L Obesity and C-reactive protein in various populations: a systematic review and meta-analysis. Obes Rev 2013, 14:232-244.
8. de Rooij SR, Nijpels G, Nilsson PM, et al. Low-grade chronic inflammation in the relationship between insulin sensitivity and cardiovascular disease (RISC) population: associations with insulin resistance and cardiometabolic risk profile. Diabetes Care 2009, 32:1295-1301.
9. Mavri A, Alessi MC, Bastelica D, et al. Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss. Diabetologia 2001, 44:2025-2031.
10. Bahceci M, Gokalp D, Bahceci S, Tuzcu A, Atmaca S, Arikan S The correlation between adiposity and adiponectin, tumor necrosis factor alpha, interleukin-6 and high sensitivity C-reactive protein levels. Is adipocyte size associated with inflammation in adults?. J Endocrinol Invest 2007, 30:210-214.
11. Marques-Vidal P, Bochud M, Bastardot F, et al. Association between inflammatory and obesity markers in a Swiss population-based sample (CoLaus Study). Obes Facts 2012, 5:734-744.
12. Schnabel RB, Yin X, Larson MG, et al. Multiple inflammatory biomarkers in relation to cardiovascular events and mortality in the community. Arterioscler Thromb Vasc Biol 2013, 33:1728-1733.
13. Kaptoge S, Di Angelantonio E, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 2012, 367:1310-1320. Emerging Risk Factors Collaboration.
14. Spranger J, Kroke A, Mohlig M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003, 52:812-817.
15. Bertoni AG, Burke GL, Owusu JA, et al. Inflammation and the incidence of type 2 diabetes: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care 2010, 33:804-810.
16. Guarner F, Malagelada JR Gut flora in health and disease. Lancet 2003, 361:512-519.
17. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science 2005, 308:1635-1638.
18. Tilg H, Moschen AR, Kaser A Obesity and the microbiota. Gastroenterology 2009, 136:1476-1483.
19. Backhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004, 101:15718-15723.
20. Ding S, Chi MM, Scull BP, et al. High-fat diet: bacteria interactions promote intestinal inflammation which precedes and correlates with obesity and insulin resistance in mouse. PLoS One 2010, 5:e12191.
21. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444:1027-1031.
22. Cani PD, Neyrinck AM, Fava F, et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 2007, 50:2374-2383.
23. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007, 56:1761-1772.
24. Ley RE, Turnbaugh PJ, Klein S, Gordon JI Microbial ecology: human gut microbes associated with obesity. Nature 2006, 444:1022-1023.
25. Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature 2009, 457:480-484.
26. Schwiertz A, Taras D, Schafer K, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring) 2010, 18:190-195.
27. Jumpertz R, Le DS, Turnbaugh PJ, et al. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr 2011, 94:58-65.
28. Duncan SH, Lobley GE, Holtrop G, et al. Human colonic microbiota associated with diet, obesity and weight loss. Int J Obes 2008, 32:1720-1724.
29. Wu GD, Chen J, Hoffmann C, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 2011, 334:105-108.
30. Russell WR, Gratz SW, Duncan SH, et al. High-protein, reduced-carbohydrate weight-loss diets promote metabolite profiles likely to be detrimental to colonic health. Am J Clin Nutr 2011, 93:1062-1072.
31. David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014, 505:559-563.
32. Everard A, Belzer C, Geurts L, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci USA 2013, 110:9066-9071.
33. Ursell LK, Haiser HJ, Van Treuren W, et al. The intestinal metabolome: an intersection between microbiota and host. Gastroenterology 2014, 146:1470-1476.
34. Kurashima Y, Goto Y, Kiyono H Mucosal innate immune cells regulate both gut homeostasis and intestinal inflammation. Eur J Immunol 2013, 43:3108-3115.
35. Moreno-Navarrete JM, Sabater M, Ortega F, Ricart W, Fernandez-Real JM Circulating zonulin, a marker of intestinal permeability, is increased in association with obesity-associated insulin resistance. PLoS One 2012, 7:e37160.
36. Ewaschuk JB, Diaz H, Meddings L, et al. Secreted bioactive factors from Bifidobacterium infantis enhance epithelial cell barrier function. Am J Physiol Gastrointest Liver Physiol 2008, 295:G1025-G1034.
37. Anderson RC, Cookson AL, McNabb WC, Kelly WJ, Roy NC Lactobacillus plantarum DSM 2648 is a potential probiotic that enhances intestinal barrier function. FEMS Microbiol Lett 2010, 309:184-192.
38. Shen TY, Qin HL, Gao ZG, Fan XB, Hang XM, Jiang YQ Influences of enteral nutrition combined with probiotics on gut microflora and barrier function of rats with abdominal infection. World J Gastroenterol 2006, 12:4352-4358.
39. Ukena SN, Singh A, Dringenberg U, et al. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS One 2007, 2:e1308.
40. Whelan K, Quigley EM Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. Curr Opin Gastroenterol 2013, 29:184-189.
41. Balakrishnan M, Floch MH Prebiotics, probiotics and digestive health. Curr Opin Clin Nutr Metab Care 2012, 15:580-585.
42. Kotzampassi K, Giamarellos-Bourboulis EJ Probiotics for infectious diseases: more drugs, less dietary supplementation. Int J Antimicrob Agents 2012, 40:288-296.
43. Karczewski J, Troost FJ, Konings I, et al. Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier. Am J Physiol Gastrointest Liver Physiol 2010, 298:G851-G859.
44. West NP, Pyne DB, Cripps AW, Christophersen CT, Conlon MA, Fricker PA Gut Balance, a symbiotic supplement, increases fecal Lactobacillus paracasei but has little effect on immunity in healthy physically active individuals. Gut Microbes 2012, 3:221-227.
45. Lamprecht M, Bogner S, Schippinger G, et al. Probiotic supplementation affects markers of intestinal barrier, oxidation, and inflammation in trained men; a randomized, double-blinded, placebo-controlled trial. J Int Soc Sports Nutr 2012, 9:45.
46. Xiao S, Fei N, Pang X, et al. A gut microbiota-targeted dietary intervention for amelioration of chronic inflammation underlying metabolic syndrome. FEMS Microbiol Ecol 2014, 87:357-367.
47. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 2008, 27:104-119.
48. Topping DL, Clifton PM Short-chain fatty acids and human colonic function: roles of resistant starch and non-starch polysaccharides. Physiol Rev 2001, 81:1031-1064.
49. Ohata A, Usami M, Miyoshi M Short-chain fatty acids alter tight junction permeability in intestinal monolayer cells via lipoxygenase activation. Nutrition 2005, 21:838-847.
50. Peng L, He Z, Chen W, Holzman IR, Lin J Effects of butyrate on intestinal barrier function in a Caco-2 cell monolayer model of intestinal barrier. Pediatr Res 2007, 61:37-41.
51. Siavoshian S, Segain JP, Kornprobst M, et al. Butyrate and trichostatin A effects on the proliferation/differentiation of human intestinal epithelial cells: induction of cyclin D3 and p21 expression. Gut 2000, 46:507-514.
52. Tang Y, Chen Y, Jiang H, Nie D Short-chain fatty acids induced autophagy serves as an adaptive strategy for retarding mitochondria-mediated apoptotic cell death. Cell Death Differ 2011, 18:602-618.
53. Suzuki T, Yoshida S, Hara H Physiological concentrations of short-chain fatty acids immediately suppress colonic epithelial permeability. Br J Nutr 2008, 100:297-305.
54. Donohoe DR, Garge N, Zhang X, et al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab 2011, 13:517-526.
55. Nofrarias M, Martinez-Puig D, Pujols J, Majo N, Perez JF Long-term intake of resistant starch improves colonic mucosal integrity and reduces gut apoptosis and blood immune cells. Nutrition 2007, 23:861-870.
56. Breuer RI, Soergel KH, Lashner BA, et al. Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial. Gut 1997, 40:485-491.
57. Walton GE, Lu C, Trogh I, Arnaut F, Gibson GR A randomised, double-blind, placebo controlled cross-over study to determine the gastrointestinal effects of consumption of arabinoxylan-oligosaccharides enriched bread in healthy volunteers. Nutr J 2012, 11:36.
58. West NP, Christophersen CT, Pyne DB, et al. Butyrylated starch increases colonic butyrate concentration but has limited effects on immunity in healthy physically active individuals. Exerc Immunol Rev 2013, 19:102-119.
59. Covington DK, Briscoe CA, Brown AJ, Jayawickreme CK The G-protein-coupled receptor 40 family (GPR40-GPR43) and its role in nutrient sensing. Biochem Soc Trans 2006, 34:770-773.
60. Le Poul E, Loison C, Struyf S, et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem 2003, 278:25481-25489.
61. Vinolo MA, Rodrigues HG, Nachbar RT, Curi R Regulation of inflammation by short chain fatty acids. Nutrients 2011, 3:858-876.
62. Kim MH, Kang SG, Park JH, Yanagisawa M, Kim CH Short-chain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice. Gastroenterology 2013, 145:396-406.
63. Sina C, Gavrilova O, Forster M, et al. G protein-coupled receptor 43 is essential for neutrophil recruitment during intestinal inflammation. J Immunol 2009, 183:7514-7522.
64. Maslowski KM, Vieira AT, Ng A, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009, 461:1282-1286.
65. Furusawa Y, Obata Y, Fukuda S, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013, 504:446-450.
66. Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 2013, 341:569-573.
67. Cools N, Ponsaerts P, Van Tendeloo VF, Berneman ZN Regulatory T cells and human disease. Clin Dev Immunol 2007, 2007:89195.
68. Konieczna P, Groeger D, Ziegler M, et al. Bifidobacterium infantis 35624 administration induces Foxp3 T regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells. Gut 2012, 61:354-366.
69. Harris K, Kassis A, Major G, Chou CJ Is the gut microbiota a new factor contributing to obesity and its metabolic disorders?. J Obes 2012, 2012:879151.
70. Laugerette F, Vors C, Geloen A, et al. Emulsified lipids increase endotoxemia: possible role in early postprandial low-grade inflammation. J Nutr Biochem 2011, 22:53-59.
71. Ghoshal S, Witta J, Zhong J, de Villiers W, Eckhardt E Chylomicrons promote intestinal absorption of lipopolysaccharides. J Lipid Res 2009, 50:90-97.
72. Amar J, Burcelin R, Ruidavets JB, et al. Energy intake is associated with endotoxemia in apparently healthy men. Am J Clin Nutr 2008, 87:1219-1223.
73. Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008, 57:1470-1481.
74. Pendyala S, Walker JM, Holt PR A high-fat diet is associated with endotoxemia that originates from the gut. Gastroenterology 2012, 142:1100-1101.
75. Ghanim H, Abuaysheh S, Sia CL, et al. Increase in plasma endotoxin concentrations and the expression of Toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: implications for insulin resistance. Diabetes Care 2009, 32:2281-2287.
76. Ghanim H, Sia CL, Upadhyay M, et al. Orange juice neutralizes the proinflammatory effect of a high-fat, high-carbohydrate meal and prevents endotoxin increase and Toll-like receptor expression. Am J Clin Nutr 2010, 91:940-949.
77. Erridge C, Attina T, Spickett CM, Webb DJ A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 2007, 86:1286-1292.
78. Manco M, Putignani L, Bottazzo GF Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev 2010, 31:817-844.
79. Neves AL, Coelho J, Couto L, Leite-Moreira A, Roncon-Albuquerque R Metabolic endotoxemia: a molecular link between obesity and cardiovascular risk. J Mol Endocrinol 2013, 51:R51-R64.
80. Wiedermann CJ, Kiechl S, Dunzendorfer S, et al. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. J Am Coll Cardiol 1999, 34:1975-1981.
81. Pussinen PJ, Tuomisto K, Jousilahti P, Havulinna AS, Sundvall J, Salomaa V Endotoxemia, immune response to periodontal pathogens, and systemic inflammation associate with incident cardiovascular disease events. Arterioscler Thromb Vasc Biol 2007, 27:1433-1439.
82. Creely SJ, McTernan PG, Kusminski CM, et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 2007, 292:E740-E747.
83. Al-Attas OS, Al-Daghri NM, Al-Rubeaan K, et al. Changes in endotoxin levels in T2DM subjects on anti-diabetic therapies. Cardiovasc Diabetol 2009, 8:20.
84. Pussinen PJ, Havulinna AS, Lehto M, Sundvall J, Salomaa V Endotoxemia is associated with an increased risk of incident diabetes. Diabetes Care 2011, 34:392-397.
85. Zweigner J, Schumann RR, Weber JR The role of lipopolysaccharide-binding protein in modulating the innate immune response. Microbes Infect 2006, 8:946-952.
86. Levels JH, Abraham PR, van den Ende A, van Deventer SJ Distribution and kinetics of lipoprotein-bound endotoxin. Infect Immun 2001, 69:2821-2828.
87. Zweigner J, Gramm HJ, Singer OC, Wegscheider K, Schumann RR High concentrations of lipopolysaccharide-binding protein in serum of patients with severe sepsis or septic shock inhibit the lipopolysaccharide response in human monocytes. Blood 2001, 98:3800-3808.
88. Blairon L, Wittebole X, Laterre PF Lipopolysaccharide-binding protein serum levels in patients with severe sepsis due to gram-positive and fungal infections. J Infect Dis 2003, 187:287-291.
89. Gonzalez-Quintela A, Alonso M, Campos J, Vizcaino L, Loidi L, Gude F Determinants of serum concentrations of lipopolysaccharide-binding protein (LBP) in the adult population: the role of obesity. PLoS One 2013, 8:e54600.
90. Moreno-Navarrete JM, Ortega F, Serino M, et al. Circulating lipopolysaccharide-binding protein (LBP) as a marker of obesity-related insulin resistance. Int J Obes 2012, 36:1442-1449.
91. Qian C, Cao X Regulation of Toll-like receptor signaling pathways in innate immune responses. Ann N Y Acad Sci 2013, 1283:67-74.
92. Kim JJ, Sears DD TLR4 and insulin resistance. Gastroenterol Res Pract 2010, 2010:212563.
93. Anand RJ, Kohler JW, Cavallo JA, Li J, Dubowski T, Hackam DJ Toll-like receptor 4 plays a role in macrophage phagocytosis during peritoneal sepsis. J Pediatr Surg 2007, 42:927-932.
94. Gosemann JH, van Griensven M, Barkhausen T, et al. TLR4 influences the humoral and cellular immune response during polymicrobial sepsis. Injury 2010, 41:1060-1067.
95. Verbon A, Dekkers PE, ten Hove T, et al. IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J Immunol 2001, 166:3599-3605.
96. Olszyna DP, Verbon A, Pribble JP, et al. Effect of IC14, an anti-CD14 antibody, on plasma and cell-associated chemokines during human endotoxemia. Eur Cytokine Netw 2003, 14:158-162.
97. Song MJ, Kim KH, Yoon JM, Kim JB Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes. Biochem Biophys Res Commun 2006, 346:739-745.
98. Tsukumo DM, Carvalho-Filho MA, Carvalheira JB, et al. Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 2007, 56:1986-1998.
99. Michelsen KS, Wong MH, Shah PK, et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 2004, 101:10679-10684.
100. Li Q, Zhang Q, Wang C, Liu X, Li N, Li J Disruption of tight junctions during polymicrobial sepsis in vivo. J Pathol 2009, 218:210-221.
101. Lai CW, Sun TL, Lo W, et al. Shedding-induced gap formation contributes to gut barrier dysfunction in endotoxemia. J Trauma Acute Care Surg 2013, 74:203-213.
102. Jorgensen VL, Nielsen SL, Espersen K, Perner A Increased colorectal permeability in patients with severe sepsis and septic shock. Intensive Care Med 2006, 32:1790-1796.
103. Hietbrink F, Besselink MG, Renooij W, et al. Systemic inflammation increases intestinal permeability during experimental human endotoxemia. Shock 2009, 32:374-378.
104. Klaus DA, Motal MC, Burger-Klepp U, et al. Increased plasma zonulin in patients with sepsis. Biochem Med 2013, 23:107-111.
105. Cani PD, Possemiers S, Van de Wiele T, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009, 58:1091-1103.
106. Naito E, Yoshida Y, Makino K, et al. Beneficial effect of oral administration of Lactobacillus casei strain Shirota on insulin resistance in diet-induced obesity mice. J Appl Microbiol 2011, 110:650-657.